HRTX News and Press, Heron Therapeutics Inc. From 08/09/22

Heron Therapeutics, Inc. (HRTX) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart – Chief Executive Officer and Chairman John Poyhonen ...

Heron Therapeutics ( NASDAQ: HRTX ) plunged 10.1% down premarket after it entered into a securities purchase agreement to sell 16.1M shares at an offering price of $3.10/share, pre-funded warrants to purchase up to 8.55M shares at purchase price of $3.0...

Heron Therapeutics press release ( NASDAQ: HRTX ): Q2 GAAP EPS of -$0.55 misses by $0.05 . Revenue of $27.63M (+23.3% Y/Y) beats by $2.98M . As of June 30, 2022, Heron had cash, cash equivalents and short-term investments of $83.5 million. Sh...

Heron Therapeutics Announces $76.5 Million Private Placement Financing PR Newswire SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by dev...

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates PR Newswire - ZYNRELEF ® launch trend continues at a strong pace with sequential quarterly product sales increase of 140% an...

Heron Therapeutics ( NASDAQ: HRTX ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.54 (+12.9% Y/Y) and the consensus Revenue Estimate is $24.65M (+10.0% Y/Y). Over the last 3 months, EPS estima...

Major earnings expected before the bell on Tuesday include: Bausch Health Companies ( BHC ) Cronos Group ( CRON ) Emerson Electric ( EMR ) Norwegian Cruise Line Holdings ( NCLH ) Workhorse Group ( WKHS ) For further details see: Notable ea...

Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 PR Newswire SAN DIEGO , Aug. 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the l...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Heron Therapeutics ( NASDAQ: HRTX ) on Thursday said it was planning to reduce its employee headcount by 34% as part of a restructuring and cost reduction plan. The plan also includes reductions and reallocations to the company's overall sales, general and administrati...